Perhaps some disappointment around the EBITDA guidance, but the results commentary did suggest a stronger than expected NPAT in H2 2024 due to cost cutting. I guess the proof will be in the pudding. Initially I was pleased by the ex covid testing revenue growth (even accounting for acquisitions), but looking at the even stronger growth in costs, this put a bit of a dampener on it. As you said, no franking credit on dividend.
Ann: Half Yearly Report and Accounts, page-3
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$26.69 |
Change
0.010(0.04%) |
Mkt cap ! $12.82B | |||
| Open | High | Low | Value | Volume |
| $26.40 | $26.69 | $26.22 | $30.22M | 1.117M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 268 | $26.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $26.69 | 931 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| SHL (ASX) Chart |